EMBEDA® Extended-Release Capsules CII: Latest Use, Abuse and Addiction News
FDA has approved updated labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules for oral consumption, CII, to incorporate abuse-deterrence studies. The updated label says EMBEDA has characteristics expected to mitigate abuse via the oral and intranasal (i.e., snorting) routes when crushed. However, the misuse of EMBEDA by these routes is still a…
Details